Category 1 vs Category 2 Peptides
What the FDA Classification Means in 2026
The FDA’s Category system for compounded peptides determines one thing above all else: whether a licensed pharmacy can legally prepare a compound for a patient. Category 1 means it can. Category 2 means it cannot — period. In late 2023, the FDA moved 19 widely used peptides to Category 2, cutting off legal compounding access for all of them. On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 of those 19 are expected to return to Category 1. As of March 2026, the FDA has not published its official updated list — and until it does, no pharmacy can legally compound any of these compounds, regardless of what has been announced publicly.
Key Takeaways
- Category 1 means a licensed compounding pharmacy can legally prepare a peptide when a physician prescribes it; Category 2 means it cannot be compounded — period
- In September 2023, the FDA moved 19 peptides to Category 2, cutting off legal compounding access for patients and providers across tissue repair, immune support, metabolic health, longevity, and cognitive compounds
- On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 of those 19 peptides will return to Category 1 — restoring legal compounding access under physician prescription
- As of March 2026, the FDA has not published its official updated list; pharmacies cannot legally compound any of these peptides until the Federal Register publishes the formal change
- Category 1 reclassification does not mean FDA approval — these remain off-label, cash-pay medications requiring a physician prescription, with no insurance coverage
Legal and compliance notice The Federal Register is the legal trigger for any reclassification — not a public announcement. Until the FDA formally publishes its updated Category 1 list, all compounds discussed below remain legally classified as Category 2. Pharmacies that begin compounding Category 2 substances before formal publication risk enforcement action from the FDA and state boards of pharmacy. Patients should confirm current legal status with their prescribing physician or a licensed compounding pharmacy before making any protocol changes.
How the Category System Works
The FDA classifies bulk drug substances used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA). These categories determine whether a licensed compounding pharmacy can legally prepare a compound for a patient.
Category 1 covers substances the FDA is actively evaluating for inclusion on its formal bulk drug substances list. Under the FDA’s interim enforcement policy, the agency does not intend to take action against a licensed compounding pharmacy for preparing a Category 1 substance — provided the pharmacy has a valid physician prescription, a Certificate of Analysis (COA) from an FDA-registered manufacturer, and meets all other conditions under Section 503A.
Category 2 covers substances the FDA has flagged as presenting significant safety risks. The FDA considers taking enforcement action against any compounder that prepares a Category 2 substance. Licensed pharmacies operating under either 503A (patient-specific, traditional pharmacies) or 503B (outsourcing facilities producing larger batches) cannot legally prepare Category 2 compounds.
| Category 1 | Category 2 | |
|---|---|---|
| Definition | Under FDA evaluation; no disqualifying safety concerns identified | Flagged for significant safety risks |
| Compounding eligibility | Yes — under 503A and 503B conditions | No — compounding prohibited |
| Legal basis | FDCA Section 503A / 503B interim enforcement policy | FDCA Section 503A / 503B |
| Quality requirement | COA from FDA-registered manufacturer required | N/A — cannot be compounded |
| FDA approval status | Not FDA-approved drugs; off-label preparations | Not applicable |
A compound moves between categories through a nomination and evaluation process. Any party — a physician, pharmacy, or patient advocacy group — can submit a citizen petition asking the FDA to reclassify a substance. The FDA then evaluates safety, clinical need, and manufacturing standards before publishing any change in the Federal Register.
The 503A and 503B frameworks differ in scope. Section 503A pharmacies compound specific medications for individual patients with a prescription. Section 503B outsourcing facilities produce larger volumes — sometimes without patient-specific prescriptions — and face stricter FDA inspection and quality standards.
Learn more about are peptides legal in the US — the 2026 updated guide.
The 2023 Crackdown: How 19 Peptides Ended Up in Category 2
On September 29, 2023, the FDA updated its bulk drug substances list and moved 19 widely used peptides from Category 1 to Category 2, cutting off legal compounding access for each one.
The FDA’s stated justifications included: immunogenicity risk (concern that injectable peptides could trigger immune reactions in some patients), manufacturing impurities (concern that compounding-grade peptide production lacked consistent purity controls), and the absence of large-scale human trial data (most of these peptides have been studied primarily in animal models, with limited Phase I or II human trial data and no Phase III randomized controlled trials).
The 19 peptides moved to Category 2 in 2023:
| Therapeutic cluster | Compounds |
|---|---|
| Tissue repair | BPC-157, TB-500 (Thymosin Beta-4) |
| Immune support | Thymosin Alpha-1, KPV (Lys-Pro-Val) |
| Metabolic health | AOD-9604, MOTS-C, Ipamorelin |
| Longevity / anti-aging | GHK-Cu (Copper Peptide), Epitalon |
| Cognitive / neurological | Semax, Selank |
| Hormonal / sleep | Kisspeptin-10, DSIP (Delta Sleep-Inducing Peptide) |
| Growth hormone secretagogues | GHRP-2, GHRP-6, CJC-1295 |
| Antimicrobial | Cathelicidin LL-37 |
| Growth factors | PEG-MGF (Pegylated Mechano Growth Factor) |
| Skin | Melanotan II |
Clinicians, compounding pharmacists, and members of Congress pushed back immediately. Their core argument: the FDA had driven patients away from licensed, quality-controlled pharmacies and toward unregulated grey-market suppliers — creating the exact safety problem the agency claimed to be preventing. The Alliance for Pharmacy Compounding (APC) sent a formal letter to the FDA in October 2023 requesting transparency about the specific safety methodology used to justify each compound’s placement.
Learn more about compounded peptides vs research chemicals: legal status, safety, and how to verify sources.
Peptides Expected to Return to Category 1
Important caveat: The following is based on the February 27, 2026 announcement by HHS Secretary Kennedy and industry analysis of existing safety data. The FDA had not published its official updated list as of March 2026. PeptideRx will update this page when the Federal Register publishes the formal change. Until then, all compounds discussed below remain legally classified as Category 2.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. stated that approximately 14 of the 19 Category 2 peptides are expected to return to Category 1. Kennedy described the original 2023 reclassification as lacking legitimate safety signals and indicated the FDA would announce formal action within weeks.
Industry analysts and regulatory experts have identified the compounds most likely to return, based on their existing safety data and evidence profiles.
Tissue repair
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found naturally in gastric juice. Research has focused on gut barrier repair, tendon and ligament healing, and inflammation reduction. The evidence base is primarily preclinical — a substantial volume of animal studies — with limited human trial data. PeptideRx rates the evidence for BPC-157 for musculoskeletal recovery as Grade B (limited human trials; strong animal model data with plausible mechanism).
TB-500 (Thymosin Beta-4) is a peptide that plays a role in actin regulation, which affects cell movement and tissue repair. Animal research has examined wound healing and cardiac tissue recovery. Human trial data remains limited. PeptideRx rates the evidence for TB-500 for tissue repair as Grade B.
Immune support
Thymosin Alpha-1 is a thymic peptide with regulatory approval as a pharmaceutical drug in over 30 countries, where it is used to support immune function in hepatitis B, hepatitis C, and oncology contexts. Its placement on the 2023 Category 2 list drew the sharpest criticism from clinicians — the compound has more established international clinical use than most other peptides on the list. PeptideRx rates the evidence for Thymosin Alpha-1 for immune modulation as Grade B(limited US human trials; international approval data with plausible mechanism).
KPV (Lys-Pro-Val) is a tripeptide fragment derived from alpha-MSH (alpha-melanocyte-stimulating hormone). Research has examined its role in gut inflammation, particularly in inflammatory bowel conditions. Evidence is primarily preclinical. PeptideRx rates the evidence for KPV for gut inflammation as Grade C (primarily animal and in vitro data).
Metabolic health
AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191). Unlike full HGH, AOD-9604 targets fat metabolism without triggering the hormonal cascade associated with full growth hormone. The compound holds FDA GRAS (Generally Recognized as Safe) status for use in food — which made its simultaneous Category 2 classification a source of significant industry criticism. AOD-9604 completed Phase II clinical trial safety evaluation, setting it apart from most other Category 2 peptides. PeptideRx rates the evidence for AOD-9604 for metabolic health as Grade B.
MOTS-C is a peptide encoded in mitochondrial DNA. Research has examined its role in insulin sensitivity and mitochondrial energy regulation. Evidence is primarily from animal models. PeptideRx rates the evidence for MOTS-C for metabolic function as Grade C.
Longevity and skin
GHK-Cu (Copper Peptide) is a naturally occurring tripeptide that binds copper. Research has examined its role in skin repair, collagen production, wound healing, and hair follicle support. The FDA added GHK-Cu to Category 1 in 2023 for topical routes of administration — the Category 2 restriction applied to injectable formulations only. PeptideRx rates the evidence for GHK-Cu for skin and tissue repair (topical) as Grade B.
Epitalon is a synthetic tetrapeptide based on a natural extract from the pineal gland. Research has examined its effects on telomerase activation and telomere length — markers of cellular aging. Evidence comes primarily from animal studies and early-stage human research. PeptideRx rates the evidence for Epitalon for longevity as Grade C.
Cognitive and neurological
Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH). It has been approved for clinical use in Russia for stroke recovery and cognitive function. No US FDA approval exists. PeptideRx rates the evidence for Semax for neuroprotection as Grade C (limited data outside the Russian clinical context).
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin. Russian research has examined anxiolytic (anxiety-reducing) effects. Evidence comes primarily from studies conducted in Russia with limited independent replication. PeptideRx rates the evidence for Selank for anxiety and cognitive support as Grade C.
Hormonal and sleep
Kisspeptin-10 is a neuropeptide that regulates gonadotropin-releasing hormone (GnRH) release. Research has examined its role in reproductive hormone regulation, with some human trial data in specific clinical contexts (hypogonadism, reproductive medicine). PeptideRx rates the evidence for Kisspeptin-10 for hormonal regulation as Grade B (limited human trials with plausible mechanism).
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide studied for sleep regulation, stress response, and hormonal modulation. Evidence is primarily from older animal research and limited human studies. PeptideRx rates the evidence for DSIP for sleep support as Grade C.
Ipamorelin is a selective growth hormone secretagogue that stimulates pituitary GH release through GHS-R1a receptor binding, with a relatively clean side effect profile compared to older GHRPs. Limited Phase I human data exists. PeptideRx rates the evidence for Ipamorelin for GH stimulation as Grade C (animal and limited Phase I human data).
Summary table
| Compound | Cluster | Evidence tier | Expected status |
|---|---|---|---|
| BPC-157 | Tissue repair | Grade B | Category 1 (expected) |
| TB-500 | Tissue repair | Grade B | Category 1 (expected) |
| Thymosin Alpha-1 | Immune support | Grade B | Category 1 (expected) |
| KPV | Immune support | Grade C | Category 1 (expected) |
| AOD-9604 | Metabolic | Grade B | Category 1 (expected) |
| MOTS-C | Metabolic | Grade C | Category 1 (expected) |
| GHK-Cu (injectable) | Longevity / skin | Grade B | Category 1 (expected) |
| Epitalon | Longevity | Grade C | Category 1 (expected) |
| Semax | Cognitive | Grade C | Category 1 (expected) |
| Selank | Cognitive | Grade C | Category 1 (expected) |
| Kisspeptin-10 | Hormonal | Grade B | Category 1 (expected) |
| DSIP | Sleep / hormonal | Grade C | Category 1 (expected) |
| Ipamorelin | GH secretagogue | Grade C | Category 1 (expected) |
All “expected” designations reflect industry analysis as of March 2026. The FDA had not published its formal updated list at time of writing.
Peptides Likely to Stay in Category 2
Approximately 5 of the 19 compounds are expected to remain restricted based on more specific and documented safety concerns. These designations are also speculative until the FDA publishes its formal list.
Melanotan II is a synthetic analog of alpha-MSH developed originally for skin tanning. Research has associated it with increased nevus (mole) activity, potential melanoma risk, and cardiovascular effects including elevated blood pressure. The safety concerns are more specific and documented than those cited for most other Category 2 peptides.
GHRP-2 and GHRP-6 are growth hormone-releasing peptides with more complex side effect profiles than isolated GH-stimulating peptides — including increased appetite, elevated cortisol, and prolactin effects. Their safety profiles have drawn more consistent regulatory concern than other peptides on the list.
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. Reports of cardiac side effects, including increased heart rate, have been associated with its use and were cited in FDA safety assessments alongside the standard immunogenicity and impurity concerns.
Cathelicidin LL-37 is a human antimicrobial peptide with immune-modulating properties. Human safety data for therapeutic use is limited, and the immunological complexity of an endogenous antimicrobial peptide used as a compounded injectable presents challenges the FDA has not resolved.
PEG-MGF (Pegylated Mechano Growth Factor) is a pegylated (chemically modified) growth factor. The pegylation itself — attaching polyethylene glycol to the peptide — raises additional safety questions beyond those applied to the non-modified compound, and clinical evidence for therapeutic use is limited.
What this Means for Patients, Providers, and Pharmacies
What changes — and what does not
| Area | Category 1 reclassification enables | Does NOT change |
|---|---|---|
| Access | Legal compounding through licensed pharmacies | Over-the-counter access — still prohibited |
| Approval status | — | FDA drug approval status — still not approved |
| Prescription requirement | — | Physician prescription still required |
| Insurance coverage | — | Still cash-pay; not covered by insurance |
| Grey-market status | — | Unregulated suppliers remain unregulated |
| Quality control | Licensed pharmacy COA and FDA-registered manufacturer required | Grey-market products still carry no quality guarantees |
For patients
Once the FDA formally publishes its updated list, patients who have been using Category 2 peptides from grey-market sources will have a legal, quality-controlled alternative. Licensed compounding pharmacies operating under Section 503A require a physician prescription, source from FDA-registered manufacturers, and provide a COA for every batch.
Compounded peptides remain off-label medications — not FDA-approved drugs. No insurance plan covers them. Costs vary by compound, dose, and pharmacy; plan to pay out of pocket.
The FDA announcement alone does not change what is legally available today. Wait for formal Federal Register publication and confirm with your prescribing physician or a licensed compounding pharmacy before changing any protocol.
For providers
Category 1 reclassification restores a legal prescribing pathway for approximately 14 compounds that have been effectively inaccessible through licensed channels since late 2023. Providers who were seeing patients turn to unregulated suppliers will have a regulated alternative to offer.
The reclassification does not change the off-label status of these compounds. Prescribing a Category 1 compounded peptide is legal; representing it as FDA-approved is not. Informed consent discussions must include the off-label nature of the therapy, the current evidence tier for the specific compound and indication, and the absence of large-scale Phase III human trial data for most of these peptides.
Direct prescriptions to licensed 503A compounding pharmacies and verify that the pharmacy uses FDA-registered bulk suppliers with current COAs.
For compounding pharmacies
Licensed compounding pharmacies cannot begin preparing any of these peptides until the FDA formally publishes its updated Category 1 list in the Federal Register. The HHS Secretary’s announcement does not constitute regulatory authorization. Preparing Category 2 compounds before formal reclassification risks enforcement action from both the FDA and state boards of pharmacy.
Once the list is published, 503A pharmacies must verify that each compound appears on the updated Category 1 list, confirm bulk suppliers are FDA-registered and hold current COAs, and document compliance with all other Section 503A conditions before compounding begins. 503B outsourcing facilities face additional requirements and should consult with regulatory counsel before resuming production of any reclassified compound.
Learn more about state-by-state peptide compounding legality: what prescribers and pharmacies must know.
Safety Risks That Reclassification Does Not Fix
Category 1 reclassification restores legal access. It does not resolve the underlying evidence gaps that exist for most of these compounds.
Most peptides expected to return to Category 1 have been studied primarily in animal models. Large-scale, long-duration randomized controlled trials in humans do not exist for the majority. Phase III efficacy and safety data — the standard required for FDA drug approval — is absent for all of them. Physicians prescribing these compounds do so in an off-label, physician-discretion context with an evidence base that is promising but incomplete.
General risks associated with injectable peptide therapy include injection-site reactions, immunogenicity (immune responses to the peptide itself), potential hormonal effects depending on the compound, and unknown long-term effects from extended use. The specific risk profile varies by compound, dose, and patient health status.
What reclassification does not solve: grey-market products
Independent testing of unregulated “research use only” peptide products — sold without prescription through online vendors — has found wrong compounds, bacterial contamination, and significant dosing errors in labeled vials. These products carry no COA, no FDA-inspected manufacturing standards, and no physician oversight. Their legal and safety status is entirely unchanged by the Category 1 reclassification.
Once compounding access is restored through licensed pharmacies, patients will have a quality-controlled alternative. All references to peptide access on PeptideRx point toward licensed compounding pharmacies and physician prescriptions.
Learn more about are research peptides safe? Quality risks, regulatory status, and how to minimize harm.
The Bottom Line
The FDA’s Category system is binary: Category 1 means a licensed pharmacy can legally compound a peptide under physician prescription; Category 2 means no legal compounding channel exists. The 2023 crackdown moved 19 important peptides to Category 2 and drove many patients toward unregulated grey-market sources — the opposite of the safety outcome the FDA intended. The February 2026 HHS announcement signals that approximately 14 of those compounds will return to Category 1, restoring a legal, quality-controlled pathway for patients and providers. But the announcement is not the legal change. Until the FDA publishes its formal updated list in the Federal Register, all 19 peptides remain Category 2. Work with a licensed physician and confirm current legal status directly with a licensed compounding pharmacy before making any protocol decisions.
Frequently Asked Questions
Are peptides FDA-approved after the 2026 reclassification?
No. Category 1 status allows licensed compounding pharmacies to prepare these compounds under a physician prescription. It does not constitute FDA drug approval. FDA approval requires a full New Drug Application (NDA) or Biologics License Application (BLA) process, including large-scale Phase III clinical trials. None of these compounds have completed that process.
Is BPC-157 legal now in 2026?
BPC-157 is expected to return to Category 1 based on the February 2026 HHS announcement — but the FDA had not published its formal updated list as of March 2026. Pharmacies cannot legally compound BPC-157 until that official Federal Register publication. Confirm current availability with a licensed compounding pharmacy.
When will compounding pharmacies start offering these peptides again?
Pharmacies may begin compounding once the FDA publishes the updated Category 1 list in the Federal Register. The HHS Secretary’s announcement does not authorize compounding. Secretary Kennedy indicated the FDA would act within weeks of the February 27 announcement; the timeline for formal publication remained uncertain as of March 2026.
Can peptides replace GLP-1 medications like semaglutide?
No direct replacement exists. GLP-1 medications like semaglutide act on appetite suppression, gastric emptying, and glucose regulation. AOD-9604 targets a fat-metabolism-specific pathway and does not act on GLP-1 receptors. MOTS-C works at the mitochondrial level on insulin sensitivity. These are distinct mechanisms with separate evidence bases. Some physicians are exploring complementary use, but no established protocol supports replacing GLP-1 therapy with these peptides.
Does insurance cover compounded peptides?
No. Compounded peptides are off-label preparations not covered by insurance. All costs are out of pocket. Cost varies by compound, dose, and pharmacy.
What are the risks of buying peptides online without a prescription?
Independent testing of unregulated peptide products has found wrong compounds, bacterial contamination, and dosing errors in labeled vials. These products have no COA, no FDA-inspected manufacturing standards, and no physician oversight. The Category 1 reclassification does not change the legal or safety status of grey-market products — it only affects licensed compounding pharmacies operating under physician prescription.
Consult a licensed physician before starting or resuming any peptide therapy. The FDA’s updated Category 1 list had not been published at the time of writing. Work with a licensed physician to understand the current legal status and your options before making any protocol changes.
References
- U.S. Food & Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov
- U.S. Food & Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Final guidance, January 7, 2025. Federal Register
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Updated July 8, 2025. FDA.gov
- The Joe Rogan Experience. Episode #2461. Robert F. Kennedy Jr. February 27, 2026
- Frier Levitt. FDA Peptide Regulation May Shift: What RFK Jr.’s Announcement Means for Compounding Pharmacies. March 2026. frierlevitt.com
- LumaLex Law. RFK Jr., Peptides & FDA Category 2: What’s Really Changing? March 2026. lumalexlaw.com
- Alliance for Pharmacy Compounding (APC). Letter to FDA Office of Compounding Quality and Compliance. October 27, 2023
- Federal Register. List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act. February 19, 2019
Disclaimer: The information on this page is for educational purposes only. PeptideRx does not provide medical advice, diagnosis, or treatment. Compounded peptides are not FDA-approved drugs. They are available through licensed compounding pharmacies under physician prescription. No compounded peptide has been proven safe and effective for any specific medical indication through the FDA’s drug approval process. All statements about regulatory status reflect publicly available information as of March 2026 and may change when the FDA publishes its formal updated list. Consult a licensed physician before starting or changing any peptide therapy protocol. Compounding pharmacies must comply with all applicable federal and state regulations, including FDCA Sections 503A and 503B.